With the launch of our brand new, state-of-the-art research facility, our primary goal is to elucidate the mechanisms by which cannabinoids mediate benefit in lung carcinoma. We will achieve this through cutting edge research using established tissue culture methods and subsequent assays designed to measure key events in cancer progression such as metastasis and proliferation.
Phytocannabinoids such as Cannabidiol (CBD) have previously been shown to increase the susceptibility of lung cancer cells to natural cancer killing cells in the body, and our work will delve deeper into this action of CBD, as well as other cannabinoids. An important hallmark of lung carcinoma to consider is its ability to quickly metastasise; this area will be quantified via widely used assays in order to investigate the effect of cannabinoids on metastasis.
Our current research plan will focus on the prevention and possible reversal of proliferation and metastasis of lung carcinoma through the action of cannabinoids. Our cumulative data will subsequently result in the production of a combinational therapy; the use of a number of cannabinoids at their peak concentrations to provide an effective treatment for those suffering from lung cancer.
Future work at our facility will include the establishment of an animal model, namely the zebrafish (Danio rerio). Through this animal model we will continue our work and show the efficacy of our cannabinoid treatment in a full organism.